Gene editing or specific inhibitors could be applied to our system to define the effects of adipokines such as adiponectin, leptin, resistin and omentin or metabolic and inflammatory pathways that impact hepatic insulin response in the setting of obesity and WAT inflammation2. The gene discussed is ITLN1; the disease is obesity disorder.